SmithKline Beecham Coreg long-term CHF data to be reviewed by FDA advisory committee.
Executive Summary
SMITHKLINE BEECHAM COREG LONG-TERM CHF DATA WILL BE REVIEWED FEB. 28 by FDA's Cardiovascular & Renal Drugs Advisory Committee. The committee will review long-term mortality and cardiovascular hospitalization data from a trial conducted in Australia and New Zealand to evaluate Coreg (carvedilol) for the treatment of moderate chronic congestive heart failure.